Bortezomib (Synonyms: PS-341; LDP-341; NSC 681239)

Name: Bortezomib
Brand: MedChemExpress
SKU: HY-10227
Rating: 5.0 (248 reviews)

Cat. No.: HY-10227 Purity: 99.80%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).

For research use only. We do not sell to patients.

CAS No. : 179324-69-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 248 publication(s) in Google Scholar

Other Forms of Bortezomib:

248 Publications Citing Use of MCE Bortezomib

Cell Proliferation/Viability Assay

: Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857. [Abstract]; Bortezomib (BTZ; 5, 10, 20 nM; 48 h) increases the expression level of γH2AX in RPMI-8226 and U266 cells.

: Bortezomib purchased from MedChemExpress. Usage Cited in: Mol Cell Biochem. 2024 Apr;479(4):843-857. [Abstract]; Bortezomib (BTZ; 10 nM; 48 h) significantly enhances the cell death of RPMI-8226.

: Bortezomib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2019 Jun 15;25(12):3630-3642. [Abstract]; H1975 cells treated with 5 μmol/L MTI-31 alone or in combination with 10 μmol/L CQ or 0.01 μmol/L PS-341.

: Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]; The accumulated SQSTM1 by either proteasome inhibitors or PPI was sensitive to autophagy mediated degradation. AGS cells were pretreated with 25 and 50nM bortezomib for 1h, and then incubated with 500nM torin 1 for 24h (g). After pretreatment with PPI for 24h in pH 7.4 or pH 6.5 condition, rapamycin (1μM) or torin 1 (500 nM) was added for another 24h (h). The protein level of SQSTM1 was measured by western blot analysis (g, h).

: Bortezomib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]; Different concentrations of two classical proteasome inhibitors Bortezomib and MG132 are added. AGS cells are either untreated or treated with Bortezomib (25 nM) or MG132 (0.1 μM) for 24 h in the absence or presence of baf A1 (100 nM).

: Bortezomib purchased from MedChemExpress. Usage Cited in: Elife. 2018 Aug 1;7:e38430. [Abstract]; Kelly cells are treated with increasing concentrations of Thalidomide and co-treated with 5 μM Bortezomib, 5 μM MLN4924, 0.5 μM MLN7243, or DMSO as a control. Following 24 h incubation, SALL4 and GAPDH protein levels are assessed by western blot analysis.

: Bortezomib purchased from MedChemExpress. Usage Cited in: BMC Cancer. 2018 Oct 11;18(1):971. [Abstract]; The reduction of MAGEC2 protein level in TRIM28-knockdown A375 cells can be inhibited by treatment with both MG132 and PS-341, and similar result is also observed in Hs 695 T cells.

: Bortezomib purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2017 Nov 15:815:147-155. [Abstract]; Shown are GFPu fluorescent images of the GFPu-HEK293 cells treated with CuSO₄ (Cu, 20 μM), HK (20 μM), HK-Cu (HC, 20 μM), or Velcade (Vel, 100 nM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All TREM receptor Isoform Specific Products:

View All Isoforms

TREM-1 TREM-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (K_i=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM)^[1]^[2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs)^[7].

IC₅₀ & Target

Ki: 0.6 nM (20S proteasome)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
5TGM1	IC₅₀	6.78 nM Compound: PS-341, Bortezomib	Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay Cytotoxicity against mouse 5TGM1 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
786-0	GI₅₀	1.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human 786-0 cells Growth inhibition of human 786-0 cells	[PMID: 24946214]
A-431	IC₅₀	28.2 nM Compound: Bortezomib	Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
A2780	IC₅₀	1.7 nM Compound: 1, bortezomib	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 18247547]
A2780	IC₅₀	28.9 nM Compound: Bortezomib	Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay Antiproliferative activity against human A2780 cells after 72 hrs by SRB assay	[PMID: 28182990]
A498	GI₅₀	0.48 nM Compound: Bortezomib, Velcade	Growth inhibition of human A498 cells Growth inhibition of human A498 cells	[PMID: 24946214]
A549	GI₅₀	3.09 nM Compound: Bortezomib, Velcade	Growth inhibition of human A549/ATCC cells Growth inhibition of human A549/ATCC cells	[PMID: 24946214]
A549	IC₅₀	0.62 μM Compound: Bortezomib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
A549	IC₅₀	13.9 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21077681]
A549	IC₅₀	2.14 μM Compound: Bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28634039]
A549	IC₅₀	2.5 nM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 28182990]
A549	IC₅₀	2135.73 nM Compound: PS-341	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27769033]
A549	IC₅₀	255 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19537716]
A549	IC₅₀	6.7 nM Compound: bortezomib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20158184]
A549	IC₅₀	9.318 μM Compound: Bortezomib	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 29426629]
A549	IC₅₀	92 nM Compound: BTZ	Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human A549 cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
ACHN	GI₅₀	0.79 nM Compound: Bortezomib, Velcade	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 24946214]
ARH-77	IC₅₀	6.07 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay Cytotoxicity against human ARH77 cells after 72 hrs by MTS assay	[PMID: 26965867]
ARH-77	IC₅₀	9.57 nM Compound: Bortezomib	Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human ARH77 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
BGC-823	IC₅₀	2890 nM Compound: Bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19747832]
BGC-823	IC₅₀	880 nM Compound: bortezomib	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 19537716]
BT-549	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human BT549 cells Growth inhibition of human BT549 cells	[PMID: 24946214]
BXPC-3	IC₅₀	11.8 nM Compound: Bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19747832]
BXPC-3	IC₅₀	16.2 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
BXPC-3	IC₅₀	19.4 nM Compound: bortezomib	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
CAKI-1	GI₅₀	0.66 nM Compound: Bortezomib, Velcade	Growth inhibition of human CAKI-1 cells Growth inhibition of human CAKI-1 cells	[PMID: 24946214]
CAL-27	IC₅₀	4.73 μM Compound: BTZ	Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells overexpressing HDAC4 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
CAL-27	IC₅₀	7.6 μM Compound: BTZ	Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human CAL-27 cells without HDAC4 expression assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
CCRF-CEM	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human CEM cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
CCRF-CEM	GI₅₀	0.35 nM Compound: Bortezomib, Velcade	Growth inhibition of human CCRF-CEM cells Growth inhibition of human CCRF-CEM cells	[PMID: 24946214]
CCRF-CEM	IC₅₀	11 nM Compound: Bortezomib	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
COLO 205	GI₅₀	1.23 nM Compound: Bortezomib, Velcade	Growth inhibition of human COLO205 cells Growth inhibition of human COLO205 cells	[PMID: 24946214]
Calu-6	IC₅₀	3.9 nM Compound: Bortezomib	Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay Inhibition of 26S proteasome beta5 subunit in human Calu6 cells using Suc-LLVY-aminoluciferin as substrate after 1hr by luminescence assay	10.1039/C2MD20060K
DLD-1	IC₅₀	0.0002 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DLD-1	IC₅₀	0.0009 μM Compound: Bortezomib, Velcade, PS-341	Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis	[PMID: 22206869]
DU-145	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human DU145 cells Growth inhibition of human DU145 cells	[PMID: 24946214]
EA.hy 926	IC₅₀	0.09 μM Compound: Bortezomib	Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human EA.hy 926 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
EKVX	GI₅₀	3.02 nM Compound: Bortezomib, Velcade	Growth inhibition of human EKVX cells Growth inhibition of human EKVX cells	[PMID: 24946214]
GES1	IC₅₀	12.6 nM Compound: PS-341	Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human GES-1 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HCC 2998	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCC2998 cells Growth inhibition of human HCC2998 cells	[PMID: 24946214]
HCT-116	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCT116 cells Growth inhibition of human HCT116 cells	[PMID: 24946214]
HCT-116	IC₅₀	0.001 μM Compound: Bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28634039]
HCT-116	IC₅₀	0.01 μM Compound: bortezomib	Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 23547757]
HCT-116	IC₅₀	1.4 nM Compound: PS-341	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27769033]
HCT-116	IC₅₀	27 nM Compound: Bortezomib	Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
HCT-116	IC₅₀	5 nM Compound: bortezomib	Inhibition of human HCT116 cell growth Inhibition of human HCT116 cell growth	[PMID: 24524217]
HCT-15	GI₅₀	1.51 nM Compound: Bortezomib, Velcade	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 24946214]
HEK-293T	IC₅₀	12 nM Compound: BTZ	Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay Antiproliferative activity against human 293T cells after 72 hrs by Cell Titer-Glo assay	[PMID: 28191850]
HEK293	CC₅₀	347 nM Compound: 1a, Bortezomib	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 21634429]
HEK293	IC₅₀	0.014 μM Compound: PS-341	Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay Inhibition of NF-kappaB activity in TNF-alpha-induced human HEK293 cells after 30 mins by luciferase assay	[PMID: 21044847]
HEK293	IC₅₀	10 nM Compound: 1, bortezomib	Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activation in human HEK293 cells after 3 hrs by luciferase reporter gene assay	[PMID: 20875739]
HEK293	IC₅₀	14 μM Compound: Bortezomib	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition Cytotoxicity against human HEK293 cells assessed as cell growth inhibition	[PMID: 33333398]
HEK293	IC₅₀	27 nM Compound: 1a, Bortezomib	Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader Inhibition of intracellular chymotrypsin-like activity of 20S proteasome in human HEK293 cells after 24 hrs by fluorescence plate reader	[PMID: 21634429]
HEK293	IC₅₀	9.7 nM Compound: Bortezomib	Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control Inhibition of NFkappaB in HEK293 cells incubated for 1 hr prior to TNF-alpha challenge measured after 3 hrs by luciferase reporter gene assay relative to control	10.1039/C2MD20060K
HET-1A	IC₅₀	25.6 nM Compound: PS-341	Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HET-1A cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HL-60	ED₅₀	0.0025 μM Compound: Bortezomib	Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay Inhibition of chymotrypsin-like activity of purified human 20S proteasome in HL60 cells using N-succinyl-Leu-Leu-Val-Tyr-AMC as substrate pre-incubated for 10 mins by fluorimetric assay	[PMID: 21973101]
HL-60	ED₅₀	2.5 nM Compound: bortezomib	Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins Inhibition of chymotrypsin-like activity of proteasome in human HL60 cells assessed as free AMC level after 10 mins	[PMID: 19422206]
HL-60	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28634039]
HL-60	IC₅₀	3.2 nM Compound: Bortezomib	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	[PMID: 28182990]
HL-60	IC₅₀	3.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21077681]
HL-60	IC₅₀	5.5 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19537716]
HL-60	IC₅₀	6.9 nM Compound: Bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19747832]
HL-60	IC₅₀	7.1 nM Compound: bortezomib	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20158184]
HL-60	IC₅₀	7.6 nM Compound: PS-341	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27769033]
HL-60(TB)	GI₅₀	1.9 nM Compound: Bortezomib, Velcade	Growth inhibition of human HL-60(TB) cells Growth inhibition of human HL-60(TB) cells	[PMID: 24946214]
HOP-62	GI₅₀	4.47 nM Compound: Bortezomib, Velcade	Growth inhibition of human HOP62 cells Growth inhibition of human HOP62 cells	[PMID: 24946214]
HOP-92	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human HOP92 cells Growth inhibition of human HOP92 cells	[PMID: 24946214]
HT-29	ED₅₀	> 20 μM Compound: Bortezomib	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 21973101]
HT-29	GI₅₀	0.95 nM Compound: Bortezomib, Velcade	Growth inhibition of human HT-29 cells Growth inhibition of human HT-29 cells	[PMID: 24946214]
HT-29	IC₅₀	3.2 nM Compound: Btz	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HUVEC	IC₅₀	11.2 nM Compound: PS-341	Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay Antiproliferative activity against HUVEC cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
HeLa	GI₅₀	168.1 μM Compound: BTZ; Product S4	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HeLa	IC₅₀	0.02 μM Compound: PS-341	Growth inhibition of human HeLa cells after 72 hrs by MTT assay Growth inhibition of human HeLa cells after 72 hrs by MTT assay	[PMID: 19428245]
HeLa	IC₅₀	20 nM Compound: Btz	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	92 nM Compound: bortezomib	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19537716]
HeLa	IC₅₀	> 200 nM Compound: Btz	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HepG2	EC₅₀	0.01 μM Compound: Bortezomib	Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay	[PMID: 29800827]
HepG2	EC₅₀	0.013 μM Compound: BTZ	Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay Cytotoxicity against human HepG2 cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
HepG2	GI₅₀	100.6 μM Compound: BTZ; Product S4	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32031798]
HepG2	IC₅₀	1.61 nM Compound: PS-341	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27769033]
HepG2	IC₅₀	25.2 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21077681]
HepG2	IC₅₀	37.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19537716]
HepG2	IC₅₀	7.5 nM Compound: bortezomib	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20158184]
Hs-578T	GI₅₀	1.02 nM Compound: Bortezomib, Velcade	Growth inhibition of human Hs 578T cells Growth inhibition of human Hs 578T cells	[PMID: 24946214]
IGROV-1	GI₅₀	2.24 nM Compound: Bortezomib, Velcade	Growth inhibition of human IGROV1 cells Growth inhibition of human IGROV1 cells	[PMID: 24946214]
K562	GI₅₀	0.007 μM Compound: Bortezomib	Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human K562 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
K562	GI₅₀	1.17 nM Compound: Bortezomib, Velcade	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 24946214]
KB	IC₅₀	59.5 nM Compound: bortezomib	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19537716]
KM12	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human KM12 cells Growth inhibition of human KM12 cells	[PMID: 24946214]
KM3/BTZ	IC₅₀	226 nM Compound: PS-341	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
L02	IC₅₀	55.5 nM Compound: PS-341	Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HL7702 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
LOX IMVI	GI₅₀	0.78 nM Compound: Bortezomib, Velcade	Growth inhibition of human LOXIMVI cells Growth inhibition of human LOXIMVI cells	[PMID: 24946214]
M14	GI₅₀	0.93 nM Compound: Bortezomib, Velcade	Growth inhibition of human M14 cells Growth inhibition of human M14 cells	[PMID: 24946214]
MCF7	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	[PMID: 24946214]
MCF7	IC₅₀	0.025 μM Compound: Bz	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 28557430]
MCF7	IC₅₀	18.37 μM Compound: Bortezomib	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	GI₅₀	1.26 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-231 cells Growth inhibition of human MDA-MB-231 cells	[PMID: 24946214]
MDA-MB-231	IC₅₀	0.003 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.017 μM Compound: Bortezomib	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28634039]
MDA-MB-231	IC₅₀	0.46 μM Compound: Bortezomib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
MDA-MB-231	IC₅₀	16.65 nM Compound: PS-341	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27769033]
MDA-MB-231	IC₅₀	3.125 μM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 29426629]
MDA-MB-231	IC₅₀	6.5 nM Compound: Bortezomib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 28182990]
MDA-MB-435	GI₅₀	0.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-435 cells Growth inhibition of human MDA-MB-435 cells	[PMID: 24946214]
MDA-MB-468	GI₅₀	1.48 nM Compound: Bortezomib, Velcade	Growth inhibition of human MDA-MB-468 cells Growth inhibition of human MDA-MB-468 cells	[PMID: 24946214]
MGC-803	IC₅₀	0.008 μM Compound: Bortezomib	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 28634039]
MGC-803	IC₅₀	5.782 nM Compound: PS-341	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 27769033]
MKN-45	IC₅₀	7.15 nM Compound: PS-341	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 27769033]
MM1.S	EC₅₀	0.002 μM Compound: BTZ	Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay Cytotoxicity against human MM1.S cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
MM1.S	IC₅₀	0.0026 μM Compound: Bortezomib	Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against dexamethasone-sensitive human MM.1S cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
MM1.S	IC₅₀	0.0032 μM Compound: Bortezomib	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
MM1.S	IC₅₀	2.5 nM Compound: BTZ	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
MOLT-4	EC₅₀	21 nM Compound: 1, bortezomib	Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells Inhibition of chymotrypsin-like activity of human 20S proteasome in Molt4 cells	[PMID: 18247547]
MOLT-4	EC₅₀	21 nM Compound: 8	Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate Inhibition of chymotrypsin-like activity of 26S proteasome in human Molt4 cells using MeOSuc-Phe-Leu-Phe-AFC substrate	[PMID: 22503349]
MOLT-4	GI₅₀	0.51 nM Compound: Bortezomib, Velcade	Growth inhibition of human MOLT4 cells Growth inhibition of human MOLT4 cells	[PMID: 24946214]
Malme-3M	GI₅₀	0.45 nM Compound: Bortezomib, Velcade	Growth inhibition of human MALME-3M cells Growth inhibition of human MALME-3M cells	[PMID: 24946214]
Multiple myeloma cancer stem cell	IC₅₀	8.4 nM Compound: BTZ	Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay Antiproliferative activity against human multiple myeloma cancer stem cells after 72 hrs by MTT assay	[PMID: 30108696]
NCI-H226	GI₅₀	0.46 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H226 cells Growth inhibition of human NCI-H226 cells	[PMID: 24946214]
NCI-H23	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 24946214]
NCI-H23	IC₅₀	0.01 μM Compound: Btz	Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H322M	GI₅₀	17.8 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H322M cells Growth inhibition of human NCI-H322M cells	[PMID: 24946214]
NCI-H460	GI₅₀	4.47 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H460 cells Growth inhibition of human NCI-H460 cells	[PMID: 24946214]
NCI-H460	IC₅₀	115 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 19537716]
NCI-H460	IC₅₀	780 nM Compound: bortezomib	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 20158184]
NCI-H522	GI₅₀	1.44 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-H522 cells Growth inhibition of human NCI-H522 cells	[PMID: 24946214]
NCI-H727	IC₅₀	0.025 μM Compound: Btz	Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H929	IC₅₀	10.85 nM Compound: Bortezomib	Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay	[PMID: 24767818]
NCI/ADR-RES	GI₅₀	12.3 nM Compound: Bortezomib, Velcade	Growth inhibition of human NCI-ADR-RES cells Growth inhibition of human NCI-ADR-RES cells	[PMID: 24946214]
OVCAR-3	GI₅₀	0.54 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR3 cells Growth inhibition of human OVCAR3 cells	[PMID: 24946214]
OVCAR-4	GI₅₀	1.95 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR4 cells Growth inhibition of human OVCAR4 cells	[PMID: 24946214]
OVCAR-5	GI₅₀	1.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR5 cells Growth inhibition of human OVCAR5 cells	[PMID: 24946214]
OVCAR-8	GI₅₀	2.63 nM Compound: Bortezomib, Velcade	Growth inhibition of human OVCAR8 cells Growth inhibition of human OVCAR8 cells	[PMID: 24946214]
PBMC	IC₅₀	2.7 nM Compound: 1	Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability by CellTiter Glo assay	[PMID: 31283222]
PBMC	IC₅₀	< 35 nM Compound: Bortezomib	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
PC-3	GI₅₀	0.04 μM Compound: Bortezomib	Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
PC-3	GI₅₀	2.63 nM Compound: Bortezomib, Velcade	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	[PMID: 24946214]
PC-3	IC₅₀	7 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20158184]
PC-3	IC₅₀	8.3 nM Compound: bortezomib	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21077681]
RAW264.7	IC₅₀	0.03 μM Compound: Bortezomib	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of TNFalpha-stimulated NF-kappaB activation by luciferase assay	[PMID: 32738985]
RKO	IC₅₀	20.8 nM Compound: Bortezomib	Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
RPMI-8226	EC₅₀	0.004 μM Compound: BTZ	Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay Cytotoxicity against human RPMI-8226 cells after 72 hrs by celltitre-glo assay	[PMID: 36608337]
RPMI-8226	GI₅₀	0.23 nM Compound: Bortezomib, Velcade	Growth inhibition of human RPMI8226 cells Growth inhibition of human RPMI8226 cells	[PMID: 24946214]
RPMI-8226	IC₅₀	0.0045 μM Compound: Bortezomib	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability measured after 72 hrs by XTT assay	[PMID: 34969245]
RPMI-8226	IC₅₀	0.0056 μM Compound: Bortezomib	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay	[PMID: 36512676]
RPMI-8226	IC₅₀	0.0064 μM Compound: BTZ	Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human RPMI-8226 cells cultured as 3D-spheroids assessed as reduction in cell viability after 48 hrs by Celltiter-Glo assay	[PMID: 34445874]
RPMI-8226	IC₅₀	0.0088 μM Compound: 3	Cytotoxicity against human RPMI8226 cells Cytotoxicity against human RPMI8226 cells	[PMID: 20727746]
RPMI-8226	IC₅₀	1.43 nM Compound: PS-341	Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI8226 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
RPMI-8226	IC₅₀	11.2 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
RPMI-8226	IC₅₀	3.88 nM Compound: Bortezomib	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 26965867]
RPMI-8226	IC₅₀	4.7 nM Compound: BTZ	Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Antiproliferative activity against human RPMI 8226 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 34445874]
RPMI-8226	IC₅₀	5.24 μM Compound: Bortezomib	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
RPMI-8226	IC₅₀	6.7 nM Compound: Bortezomib	Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by SRB assay	[PMID: 28182990]
RPMI-8226	IC₅₀	7.96 nM Compound: Bortezomib	Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 24767818]
RPMI-8226	IC₅₀	80 nM Compound: Bortezomib	Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin assay	[PMID: 38381886]
RPMI-8226	IC₅₀	9.5 nM Compound: PS-341, Bortezomib	Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay Cytotoxicity against human RPMI8226 cells after 48 to 72 hrs by SRB assay	[PMID: 24119559]
RXF 393	GI₅₀	0.71 nM Compound: Bortezomib, Velcade	Growth inhibition of human RXF393 cells Growth inhibition of human RXF393 cells	[PMID: 24946214]
SF-268	GI₅₀	1.17 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF268 cells Growth inhibition of human SF268 cells	[PMID: 24946214]
SF-295	GI₅₀	1.7 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF295 cells Growth inhibition of human SF295 cells	[PMID: 24946214]
SF-539	GI₅₀	0.59 nM Compound: Bortezomib, Velcade	Growth inhibition of human SF539 cells Growth inhibition of human SF539 cells	[PMID: 24946214]
SK-MEL-2	GI₅₀	1.07 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-2 cells Growth inhibition of human SK-MEL-2 cells	[PMID: 24946214]
SK-MEL-28	GI₅₀	0.46 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-28 cells Growth inhibition of human SK-MEL-28 cells	[PMID: 24946214]
SK-MEL-5	GI₅₀	0.68 nM Compound: Bortezomib, Velcade	Growth inhibition of human SK-MEL-5 cells Growth inhibition of human SK-MEL-5 cells	[PMID: 24946214]
SK-OV-3	GI₅₀	13.8 nM Compound: Bortezomib, Velcade	Growth inhibition of human SKOV3 cells Growth inhibition of human SKOV3 cells	[PMID: 24946214]
SK-OV-3	IC₅₀	1.62 nM Compound: PS-341	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27769033]
SK-OV-3	IC₅₀	12.9 nM Compound: Bortezomib	Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay Cytotoxicity against human SKOV3 cells assessed as decrease in cell viability after 4 days by CellTiter-Glo assay	[PMID: 29767973]
SK-OV-3	IC₅₀	130 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 19537716]
SK-OV-3	IC₅₀	151 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 20158184]
SK-OV-3	IC₅₀	66.8 nM Compound: bortezomib	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 21077681]
SN12C	GI₅₀	1.1 nM Compound: Bortezomib, Velcade	Growth inhibition of human SN12C cells Growth inhibition of human SN12C cells	[PMID: 24946214]
SNB-19	GI₅₀	2.04 nM Compound: Bortezomib, Velcade	Growth inhibition of human SNB19 cells Growth inhibition of human SNB19 cells	[PMID: 24946214]
SNB-75	GI₅₀	2.04 nM Compound: Bortezomib, Velcade	Growth inhibition of human SNB75 cells Growth inhibition of human SNB75 cells	[PMID: 24946214]
SR	GI₅₀	0.85 nM Compound: Bortezomib, Velcade	Growth inhibition of human SR cells Growth inhibition of human SR cells	[PMID: 24946214]
SW-620	GI₅₀	0.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 24946214]
SW1990	IC₅₀	79.06 nM Compound: PS-341	Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay Antiproliferative activity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 27769033]
SW480	IC₅₀	12.3 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 21077681]
SW480	IC₅₀	50 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19537716]
SW480	IC₅₀	6.1 nM Compound: bortezomib	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 20158184]
T47D	GI₅₀	0.6 nM Compound: Bortezomib, Velcade	Growth inhibition of human T47D cells Growth inhibition of human T47D cells	[PMID: 24946214]
THP-1	IC₅₀	6.28 nM Compound: BTZ	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 37979441]
TK-10	GI₅₀	1 nM Compound: Bortezomib, Velcade	Growth inhibition of human TK10 cells Growth inhibition of human TK10 cells	[PMID: 24946214]
TOV21G	IC₅₀	16.7 nM Compound: Bortezomib	Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
U-251	GI₅₀	1.55 nM Compound: Bortezomib, Velcade	Growth inhibition of human U251 cells Growth inhibition of human U251 cells	[PMID: 24946214]
U-266	GI₅₀	0.001 μM Compound: Bortezomib	Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay Antiproliferative activity against human U266 cells after 72 hrs by calcein AM staining based fluorescence assay	[PMID: 28441582]
U-266	IC₅₀	11.63 nM Compound: Bortezomib	Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human U266B1 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay	[PMID: 29934218]
U-266	IC₅₀	12.2 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19747832]
U-266	IC₅₀	12.5 nM Compound: PS-341	Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human U266 cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
U-266	IC₅₀	2.45 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 19537716]
U-266	IC₅₀	5.73 nM Compound: Bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTS assay Cytotoxicity against human U266 cells after 72 hrs by MTS assay	[PMID: 26965867]
U-266	IC₅₀	8.8 nM Compound: bortezomib	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 20158184]
U-87MG ATCC	IC₅₀	7.86 μM Compound: Bortezomib	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin assay	[PMID: 38381886]
UACC-257	GI₅₀	0.59 nM Compound: Bortezomib, Velcade	Growth inhibition of human UACC257 cells Growth inhibition of human UACC257 cells	[PMID: 24946214]
UACC-62	GI₅₀	0.91 nM Compound: Bortezomib, Velcade	Growth inhibition of human UACC62 cells Growth inhibition of human UACC62 cells	[PMID: 24946214]
UO-31	GI₅₀	1.05 nM Compound: Bortezomib, Velcade	Growth inhibition of human UO31 cells Growth inhibition of human UO31 cells	[PMID: 24946214]
WM 266-4	IC₅₀	0.035 μM Compound: Bortezomib, Velcade, PS-341	Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay Cytotoxicity against human WM266.4 cells after 72 hrs by ATPlite assay	[PMID: 22206869]

In Vitro

Bortezomib (PS-341) (100 nM; 8 hours) results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1^[1].
Bortezomib (PS-341) (5-100 nM; 20 hours) induces apoptosis in mantle-cell lymphoma (MCL) cell lines^[3].
Bortezomib (PS-341) (20 nM; 1-14 hours) induces Noxa up-regulation in both MCL cell lines^[3].
The IC₅₀ of Bortezomib (PS-341) is found to be 2.46 nM for 26S proteasome in the B16F10 cells^[4].
Bortezomib (PS-341) suppresses several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	PC-3 cells
Concentration:	100 nM
Incubation Time:	8 hours
Result:	Resulted in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1.

Apoptosis Analysis^[3]

Cell Line:	JVM-2, Granta-519, Jeko, REC-1 cells (MCL cell lines)
Concentration:	5-100 nM
Incubation Time:	20 hours
Result:	The median LD50 for these MCL cell lines was 31 nM (range, 18.2-60.1 nM).

Western Blot Analysis^[3]

Cell Line:	wtp53 (Granta-519), mutp53 (Jeko) cells
Concentration:	20 nM
Incubation Time:	1, 2, 4, 6, 14 hours
Result:	Noxa up-regulation was detected between 2 to 4 hours after bortezomib (PS-341).

In Vivo

Bortezomib (PS-341) (0.3-1 mg/kg; i.v.; once weekly for 4 weeks) inhibits PC-3 Tumor Growth in Nude Mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice (xenograft tumor model bearing PC-3 cells)^[1]
Dosage:	0.3, 1 mg/kg
Administration:	Intravenous injection; once weekly for 4 weeks
Result:	Resulted in a significant decrease in tumor growth ~60% at dose of 1 mg/kg.

Clinical Trial

Molecular Weight

384.24

Formula

C₁₉H₂₅BN₄O₄

CAS No.

179324-69-7

Appearance

Solid

Color

White to off-white

SMILES

OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

Ethanol : 66.67 mg/mL (173.51 mM; ultrasonic and warming and heat to 60°C)

DMSO : 50 mg/mL (130.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6025 mL	13.0127 mL	26.0254 mL
5 mM	0.5205 mL	2.6025 mL	5.2051 mL
10 mM	0.2603 mL	1.3013 mL	2.6025 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 4 mg/mL (10.41 mM); Clear solution

This protocol yields a clear solution of ≥ 4 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (40.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.51 mM); Clear solution
Protocol 6

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 7

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 8

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 9

Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.5 mg/mL (1.30 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (282 KB) SDS (557 KB)

COA (251 KB) HNMR (198 KB) LCMS (349 KB)

Handling Instructions (2659 KB)

References

[1]. Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [Content Brief]

[2]. Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24. [Content Brief]

[3]. Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64. [Content Brief]

[4]. Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9. [Content Brief]

[5]. Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12(67):471-80. [Content Brief]

[6]. Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281(2):1107-18. [Content Brief]

[7]. Wang Y, et al. TREM2-Mediated Cholesterol Efflux in Macrophages Inhibits Anti-Tumor Immunity via Limitation of CD4+ T and NK Cells. Adv Sci (Weinh). 2025 Oct 20:e06995. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.6025 mL	13.0127 mL	26.0254 mL	65.0635 mL
	5 mM	0.5205 mL	2.6025 mL	5.2051 mL	13.0127 mL
	10 mM	0.2603 mL	1.3013 mL	2.6025 mL	6.5064 mL
	15 mM	0.1735 mL	0.8675 mL	1.7350 mL	4.3376 mL
	20 mM	0.1301 mL	0.6506 mL	1.3013 mL	3.2532 mL
	25 mM	0.1041 mL	0.5205 mL	1.0410 mL	2.6025 mL
	30 mM	0.0868 mL	0.4338 mL	0.8675 mL	2.1688 mL
	40 mM	0.0651 mL	0.3253 mL	0.6506 mL	1.6266 mL
	50 mM	0.0521 mL	0.2603 mL	0.5205 mL	1.3013 mL
	60 mM	0.0434 mL	0.2169 mL	0.4338 mL	1.0844 mL
	80 mM	0.0325 mL	0.1627 mL	0.3253 mL	0.8133 mL
	100 mM	0.0260 mL	0.1301 mL	0.2603 mL	0.6506 mL

Bortezomib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Bortezomib (Synonyms: PS-341; LDP-341; NSC 681239)

Customer Review

Other Forms of Bortezomib:

248 Publications Citing Use of MCE Bortezomib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All TREM receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Bortezomib Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Bortezomib (Synonyms: PS-341; LDP-341; NSC 681239)

Customer Review

Other Forms of Bortezomib:

Bortezomib Related Antibodies

248 Publications Citing Use of MCE Bortezomib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All TREM receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Bortezomib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Bortezomib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report